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Abstract
Background: Accelerated hypofractionation is an attractive approach for adjuvant whole breast radiotherapy. In
this study we evaluated the adverse effects at least 3 years post an accelerated hypofractionated whole breast
radiotherapy schedule.
Methods: From October 2004 to March 2006, 39 consecutive patients aged over 18 years with pTis, pT1-2, pN0-1
breast adenocarcinoma who underwent conservative surgery were treated with an adjuvant accelerated
hypofractionated radiotherapy schedule consisting of 34 Gy in 10 daily fractions over 2 weeks to the whole breast,
followed after 1 week by an electron boost dose of 8 Gy in a single fraction to the tumour bed. Skin and lung
radiation toxicity was evaluated daily during therapy, once a week for one month after radiotherapy completion,
every 3 months for the first year and from then on every six months. In particular lung toxicity was investigated in
terms of CT density evaluation, pulmonary functional tests, and clinical and radiological scoring. Paired t-test, Chi-
square test and non-parametric Wilcoxon test were performed.
Results: After a median follow-up of 43 months (range 36-52 months), all the patients are alive and disease-free.
None of the patients showed any clinical signs of lung toxicity, no CT-lung toxicity was denoted by radiologist on
CT lung images acquired about 1 year post-radiotherapy, no variation of pulmonary density evaluated in terms of
normalised Hounsfield numbers was evident. Barely palpable increased density of the treated breast was noted in
9 out of 39 patients (in 2 patients this toxicity was limited to the boost area) and teleangectasia (<1/cm
2) limited
to the boost area was evident in 2 out of 39 patients. The compliance with the treatment was excellent (100%).
Conclusion: The radiotherapy schedule investigated in this study (i.e 34 Gy in 3.4 Gy/fr plus boost dose of 8 Gy in
single fraction) is a feasible and safe treatment and does not lead to adjunctive acute and late toxicities. A longer
follow up is necessary to confirm these favourable results.
Background
Breast radiation therapy after conservative surgery is
now widely accepted as a standard of care for patients
with early breast cancer. Moreover breast conserving
therapy has become an accepted treatment option
over radical mastectomy for stage I - II breast tumour
[1-3].
The conventional radiation course consists of 50 Gy in
25 daily fractions of 2 Gy on the whole breast usually
followed by the addition of a boost dose to the tumour
b e do f1 0t o1 6G yi n5-8d a i l yf r a c t i o n sr e s u l t i n gi n
overall 6 - 7 week treatment.
However, in certain patient populations like the
elderly and those living far from radiation facilities,
adjuvant breast radiotherapy appears to be underutilized
because of the substantial length of treatment. * Correspondence: pinnaro@ifo.it
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iod of time could effectively be much more convenient
for these patients. That is, a shorter schedule of radio-
therapy, as an accelerated hypofractionated regimen,
could indeed improve the use of breast conserving ther-
apy helping to knock down the “logistical barriers"(in
terms of age, aged-related morbidity, time, travel diffi-
culties, absence from family and job, cost etc) and con-
sequently providing more women with this option. This
accelerated hypofractionated approach is based on the
radiobiologic model that a lower total dose delivered in
fewer, larger fractions over a shorter period of time is at
least as effective as the traditional longer schedule.
The relationship between total dose, fraction size and
tissue response is described by the a/b value (expressed
in Gy) in Linear Quadratic (LQ) model [4]. Increasing
evidence from randomized trials comparing conventional
radiotherapy schedules to different hypofractionated ones
in whole breast irradiation after conserving surgery show
that breast adenocarcinoma may be associated with lower
a/b value than previously thought and closer to those of
late-reacting healthy tissues [5-9]. The LQ model sug-
gests that, when the a/b ratio for the tumour is similar to
that of the surrounding late-responding normal tissue,
the hypofractionated regimen may be equally or poten-
tially more effective than the conventional one [10]. On
this basis patients at our Institute who refused to spend 6
to 7 weeks in radiotherapy after breast conserving sur-
gery were offered an accelerated hypofractionated radia-
tion therapy schedule consisting of 10 daily fractions of
3.4 Gy to whole breast plus a boost dose of 8 Gy in a sin-
gle fraction to the tumour bed.
The paper aims to report a preliminary analysis focus-
ing on the early and late skin and lung toxicity after this
accelerated hypofractionated regimen. Lung toxicity was
investigated in terms of CT density evaluation, pulmon-
ary functional tests, and clinical and radiological scoring.
Methods
From October 2004 to March 2006, 39 consecutive
patients aged over 18 years with pTis, pT1-2, pN0-1
breast adenocarcinoma who underwent conservative
surgery and who refused adjuvant conventional radio-
therapy regimen (50 Gy in 25 daily fractions to the
w h o l eb r e a s tf o l l o w e db y1 0-1 6G yi n5-8d a i l yf r a c -
tions to the tumour bed) were treated with an adjuvant
accelerated hypofractionated radiotherapy schedule. This
consisted of 34 Gy in 10 daily fractions over 2 weeks to
the whole breast, followed by an electron boost dose of
8 Gy in a single fraction to the tumour bed after 1
week. The protocol has been approved by the local
Ethics and Scientific Committee. All patients provided a
written informed consent. The median follow-up from
the start of radiotherapy was 43 months (range, 36-52
months). The patient and tumour characteristics are
listed in Table 1. Data on potential confounding factors
such as pulmonary pre-morbidity, smoking habits and
adjuvant chemotherapy and/or hormotherapy were also
registered for each patient.
Out of 39 patients, 12 (31%) were treated with adju-
vant chemotherapy before radiotherapy, either with
CMF (cyclophosphamide 600 mg/m
2, methotrexate 40
Table 1 Patient and tumor main characteristics
Age (years) median (range) 63 (47-81)
Menopausal status
Pre 7
Post 32
Smoking habits
Smokers/Ex smokers 9
Non smokers 30
Histologic type
Invasive ductal 31
Invasive lobular 1
Mixed ductal/lobular 1
Other 3
DCIS 3
Grading
1 8
2 22
3 7
Not evaluable 2
Tumor diameter (mm) median (range) 14 (1-30)
pT stage
pTis 3
pT1 mic 1
pT1a 5
pT1b 5
pT1c 18
pT2 7
pN stage (not including DCIS)
pN stage
pN0 31
pN1 (≤ 3) 5
Estrogen receptor status
positive 37
negative 2
Progesteron receptor status
positive 34
negative 5
Chemotherapy
Yes 12
No 27
Ormonotherapy
No 7
Tamoxifen 17
Anastrozole 15
Follow-up (months) median (range) 43(36-52)
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2, 5-FU 600 mg/m
2 d 1 and d8 q 4 weeks × 6) in 6
patients or FEC (5-FU 600 mg/m
2, epirubicin 60 mg/m
2,
cyclophosphamide 600 mg/m
2 d1q3w e e k s×6 )i n2
patients or EC (epirubicin 60 mg/m
2, cyclophosphamide
600 mg/m
2 d1 q 3 weeks × 4) followed by Docetaxel
100 mg/m
2 d1 q 3 weeks × 4) in 4 patients. The adju-
vant chemotherapy had generally been completed 3 to 4
weeks before starting radiotherapy and before baseline
pulmonary function tests.
Adjuvant hormotherapy, with tamoxifen (associated
with luteinizing hormone-releasing hormone analogue
in 1 patient) or anastrozole, if indicated, was given
simultaneously with radiotherapy.
Radiobiological Considerations
In order to compare the “standard” radiotherapy treatment
consisting of 50 Gy in 25 fractions delivered in an overall
time of 33 days to our different fractionation schedule of
34 Gy in 10 fractions delivered in an overall time of 12
days, the Normalized Total Dose (NTD) was calculated.
The additional dose of 8 Gy in one fraction given to the
tumour bed was also considered. Tumour bed irradiation
was performed a week after the end of whole breast radio-
therapy, so for the “boost” volume the overall treatment
time was 19 days and the total dose was 42 Gy.
The normalized total dose (NTD), or the isoeffective
dose in 2 Gy fractions, was calculated using the Withers
formula [11]:
NTD D d) =+ + [/ / (/ ) ]  2
where D is the total physical dose, d is the dose per
fraction, and a/b is the tissue-specific ratio. In this work
we assumed an a/b ratio of 3 Gy for late-responding
normal tissues (lung), 3.4 Gy for late change in breast
appearance, 4.6 Gy [8] and 10 Gy for tumor control and
10 Gy for skin (considering early reaction). To take into
account the different overall treatment time the NTD
was corrected in NTDT according with the formula [12]:
NTD NTD t T  D T t prolif =+ − ()
where “T” is the overall treatment time (in days) for
the schedule under consideration that delivered a nor-
malized total dose NTD; “t” is the overall treatment
time of a conventionally fractionated scheme (2 Gy/frac-
tion, five fractions/week) that would deliver a radiation
dose equal to “NTDt“.
“t” was calculated as follows: t = ((NTD/2) × (7/5),
subtracting 2 days for the weekend if necessary.
The difference (t -T) has positive values for treatment
abbreviation and indicates the days of acceleration. Dpro-
lif is the dose recovered per day due to proliferation, to
compensate for rapid cell repopulation. For cancer a
Dprolif value of 0.7 Gy/d was considered, as a mean
value in the range 0.5 - 0.9 estimated for most tumours
from a review of studies in literature [12,13]. For normal
tissues, a Dprolif value of 0.2 Gy/d was adopted as
reported by other authors [14,15].
In Table 2 the results of the radiobiological calculation
are summarised. Thus, correcting differences in overall
Table 2 Radiobiological equivalence of schedule used in this study.
Treatment Breast Tumor bed
Schedule d(Gy) × (n. fr) 3.4 × 10 3.4 × 10 plus 8 × 1
Total physical dose (Gy) 34 42
Treatment time (days) 12 19
Normal tissue - late effect
Lung (a/b = 3 Gy) NTD2 (Gy) 43.5 61.1
Acceleration (days) * Dprolif 18 * 0.2 24 * 0.2
NTDT (Gy) 47.1 65.9
Normal breast (a/b = 3.4 Gy) NTD2 (Gy) 42.8 59.7
Acceleration (days) * Dprolif 17 * 0.2 21 * 0.2
NTDT (Gy) 46.2 63.9
Tumor
Breast Tumor (a/b = 4.6 Gy) NTD2 (Gy) 41.2 56.5
Acceleration (days) * Dprolif 17 * 0.7 19 * 0.7
NTDT (Gy) 53.1 69.8
Cancer cells (a/b = 10 Gy) NTD2 (Gy) 38 50
Acceleration (days) * Dprolif 13 * 0.7 14 * 0.7
NTDT (Gy) 47.1 59.8
Abbreviations: NTD2 is the normalized total dose at 2 Gy fraction, NTDT is the normalized total dose at 2 Gy fraction corrected for time acceleration (see text).
Acceleration indicates the difference (t -T) respect to the conventional treatment. Dprolif is the dose recovered per day due to proliferation, to compensate for
rapid cell repopulation.
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plus a boost of 8 Gy in one fraction delivered within 19
days is biologically equivalent to 59-70 Gy in 2 Gy/fr,
considering the tumour bed volume, according to the a/
b values of 10 and 4.6 Gy, respectively.
Radiotherapy Treatment
Patients were treated in a breast board in the supine
position with both arms extended overhead and sup-
ported by a dedicated arm rest. 3D Treatment plans
(Eclipse Treatment Planning System- Varian CA) were
based on CT images acquired by a dedicated radiother-
apy AQ Sim CT scan (Philips Medical systems, Nether-
lands) with a 5 mm spacing from the apex of the lungs
to the diaphragm, including the whole lung and breast.
The Clinical Target Volume (CTV) consisted of the
whole breast parenchyma. The Planning Target Volume
(PTV) was obtained by adding a 1 cm margin to the
CTV except in the direction of the skin’s surface.
Organs at risk (OARs) such as omolateral lung - from
the apex to the base - and the heart in the left-side
breast cancer were also outlined in every slice.
3D conformal radiotherapy was delivered by two
opposed 6 MV photon beams (Varian LINAC 2100
endowed with a Millenium multileaf collimator). Wedge
compensation was used to ensure a uniform dose distri-
bution to the target volume of -5% and +7% [16]. The
total dose was 34 Gy delivered in 10 daily fractions, 3.4
Gy per day, 5 days a week; the dose was normalized at
the ICRU (International Commission on Radiation Units
and Measurements) reference point [16].
Portal images were taken to check positioning just
before the first session and then every two sessions.
The boost dose of 8 Gy (prescribed to the 90% refer-
ence isodose) was administered in a single fraction by a
6 to 12 MeV electron field according to the location of
the tumour bed defined by metallic clips purposefully
positioned at the time of the surgery and/or by compu-
ter tomography analysis. Dose on the lungs (considering
only the homolateral) was kept below the limit of 15.6
Gy to no more than 12.5% of the volume, 10.1 Gy to no
more than 14.5% and 7.8 Gy to no more than 16%
(Table 3, i.e equivalent to V20 Gy<12.5%, V13<14.5%
and V10<16% respectively at 2 Gy/fr regime considering
an a/b value for the lung equal to 3 Gy [17,18]).
Dose-volume histograms (DVHs) analysis were calcu-
lated and registered for all OARs.
Pulmonary function tests (PFTs)
Pulmonary function tests were performed before the
beginning of radiotherapy and then after 6, 12 and 24
months from the end of radiotherapy.
Forced Vital Capacity (FVC), Forced Expiratory
Volume in 1 s (FEV1) and Carbon Monoxide Diffusing
Capacity (DLCO) acquired with the single breath techni-
que have been measured with a Quark PFT Cosmed spi-
rometer. Measurements are expressed as absolute and
relative values (normalised for weight, height, sex and age
of patients in agreement with ERS 93 parameters) [19].
Hemogas analysis was performed with blood sampling
from the radial arteria or omeral arteria and analysed
with the ABL 520 blood gas analyzer system.
The PaO2,ST (i.e. standard) was standardized to a
PaCO2 of 40 mmHg from the PaO2 and PaCO2 values
and corrected for the effect of hyperventilation [20].
The evaluation of pulmonary functionary was per-
formed on 38 patients (one patient refused post-radio-
therapy PFTs and one-year post-radiotherapy CT). Nine
patients were, or had been in the past, smokers.
Toxicity
Radiation toxicity was evaluated daily during therapy,
once a week for one month after radiotherapy comple-
tion, every 3 months for the first year and from then on
every six months.
The National Cancer Institute Common Toxicity Cri-
teria, version 2, was used to assess the acute toxicity [21].
The SOMA/LENT scoring system was used for the
assessment of late sequelae [22].
The National Cancer Institute Common Toxicity Cri-
teria, version 4, was used to assess the lung toxicity
based on pulmonary function tests [23].
CT scan evaluation
In order to evaluate density of omolateral lung, a chest
CT scan (with the patient in the same treatment
Table 3 Volume and dosimetric parameters related to lung
Minimum Average ± sd Maximum
Lung Volume (cm
3) 807 1403 ± 305 2050
Mean Lung Dose (Gy) 0.76 1.69 ± 0.7 4.44
V7.8 Gy (%) 1.1 4.5 ± 2.3 13.0
V10.1Gy (%) 0.9 4.1 ± 2.1 12.2
V15.6Gy (%) 0.6 3.4 ± 1.9 10.9
Maximum lung distance (mm) 21 4 ± 42 3
Abbreviations: sd = standard deviation, Vx = the % of lung volume receiving at least the dose X in Gy.
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Out of 39 patients, 38 underwent chest CT scans before
(1 patient refused one-year post-radiotherapy CT and
post-radiotherapy PFTs).
A radiologist with specific experience (blinded to the
side of irradiation) was asked to assess differences
between the two lungs and to score CT- lung altera-
tion according to Nishioka et al. [24] scoring system,
summarized as follows. Grade 0: no significant changes
in the radiation fields; Grade 1: only pleural thickening
is seen in the radiation fields; Grade 2 pulmonary
changes (plaque-like or heterogeneous density) are
seen in less than 50% area of the radiation fields;
Grade 3: pulmonary changes are seen in more than
50% area of the radiation fields.
We also evaluated the radiation induced pulmon-
ary density changes by a modified Wennemberg et
al. [25] CT-based method. The CT scan performed
before radiotherapy for treatment planning and the
one-year follow-up CT scan were considered. On
both sets two levels were examined: CT slices corre-
sponding to the isocenter and the boost area. For
lung evaluation, regions of interest of about 1 cm
diameter immediately below the thoracic wall were
drawn in the irradiated and non irradiated lung and
in the pre-radiotherapy and post-radiotherapy (1
year after) CT scan. The mean density and the stan-
dard deviation within the area of interest were cal-
culated by TPS tools. Density was evaluated in
Hounsfield Units (HU) representing the mean
attenuation of the tissue examined, in a scale where
-1000 and 0 are the air and the water density values,
respectively. To correct lung density differences due
to breathing, the contra-lateral mean lung density
value was subtracted from that of the omolateral
lung (normalized HU). Differences between HU
values before and after radiotherapy were assessed
for each patient.
Statistical analysis
A t test and Chi-square test were performed to investi-
gate whether there was any correlation between the
measurements of pulmonary fibrosis through the
method of Hounsfield numbers, chemotherapy (CT),
smoking history (current and ex smokers vs. Non-smo-
kers), age and dosimetric parameters. The dosimetric
parameters investigated were MLD (the mean lung dose
expressed in Gy), V15.6 Gy, V7.8 Gy, V3.6 Gy (the % of
lung volume receiving at least 15.6 Gy, 7.8 Gy and 3.6
Gy, respectively).
The non-parametric Wilcoxon test for paired samples
was performed between data of FPT parameters
recorded before and after treatment. A p-value < 0.05
was considered statistically significant.
Results
After a median follow-up of 43 months (range, 36-52
months), all the patients are alive and disease-free.
There were no major nor minor treatment deviations
resulting in 100% compliance with the treatment.
Acute skin toxicity against the grade evaluated accord-
ing to the CTC v.2 criteria is shown in Figure 1.
Of the 39 patients, 19 (49%) had no acute skin toxicity
at all, 16 (41.0%) had Grade 1, consisting in all cases in
faint erythema, and 4 patients (10%) presented Grade 2
toxicity consisting in moderate erythema. The peak inci-
dence of Grade 2 acute skin toxicity occurred at 1 week
after the treatment ending with two patients having
reactions confined to the boost area. No patient suffered
Grade 3 or more acute skin toxicity. Neither was there
any correlation found between acute skin toxicity and
breast volume nor previous adjuvant chemotherapy
(with or without antracyclines).
Figure 2 summarized late breast toxicity according to
the SOMA/LENT scoring system.
At the time of analysis with a minimum follow- up of
36 months, Grade 1 late breast toxicity was present in
11 patients (28%) and consisted of barely palpable
increased density in nine patients (in 2 patients this
toxicity was limited to the boost area) and teleangectasia
(<1/cm
2) limited to the boost area in 2 patients. No
toxicity grade 2 or more was observed. Also in this case
no correlation was found with breast volume and with
previous adjuvant chemotherapy.
In Figure 3 the mean dose volume histogram for the
lung is shown together with the less and most favorable
histograms, dose volume constraints in terms of 2 Gy
per fraction equivalence are always respected.
None of the 39 patients presented symptoms of radia-
tion pneumonitis or any other respiratory symptoms
(coughing and/or dyspnea with or without fever) or
Figure 1 Skin acute toxicity based on ctc v.2 criteria versus
toxicity grade observed for the 39 patients.
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radiotherapy.
No CT-lung toxicity according to Nishioka et al.[24]
scoring system was denoted by radiologist on CT lung
images acquired about 1 year post-radiotherapy.
A t-test was performed to investigate the correlation
between the variation of pulmonary density evaluated in
terms of normalised Hounsfield numbers and age, hor-
monal treatment and dosimetric parameters (p > 0.05,
data not shown). No significant correlation was found
with chemotherapy (p > 0.05) as it can be seen from the
results reported in Table 4.
The potential impact of the treatment on breathing
was investigated (Table 5).
In particular a ≥G1 toxicity based on DLCO was
observed in 78% and 22% of patients who did/did not
receive adjuvant chemotherapy before radiotherapy,
respectively (p = 0.006, Table 5). The ≥G2 toxicity based
on DLCO was observed in 38% and 6% of patients who
did/did not receive adjuvant chemotherapy before radio-
therapy, respectively (p = 0. 034, Table 5). These differ-
ences were lost both for ≥G1 than for ≥G2 at 2-year
post-radiotherapy, indicating a recovery over time of the
capacity of diffusivity.
No correlation was observed in toxicity (grade ≥G2
and ≥G1) based on DLCO with TAM while a correla-
tion was observed with smoking habits before
radiotherapy.
FEV1%, expressed as a percentage in comparison to
the predicted value for each patient, before and at 2
years post-radiotherapy was not statistically different in
patients who did or did not receive chemotherapy. No
correlation was observed with TAM while a significant
correlation was found with smoking habits for ≥G1 at 2-
Figure 3 Minimum (broken line), mean (solid line), maximum (dotted line) cumulative lung dose volume histograms for
hypofractionated breast radiotherapy. Filled circles indicate dose volume constraints used for planning, equivalent to V20 Gy<12.5%,
V13<14.5% and V10<16% respectively at 2 Gy/fr regime considering an a/b value for the lung equal to 3 Gy.
Table 4 Hounsfield values in ROIs delineated on CT
images before and post-RT.
chemotherapy no chemotherapy p-value (t-test)
(average ± sd) (average ± sd)
Isoplan pre-RT -815 ± 32 -817 ± 32 0.419
isoplan post-RT -813 ± 43 -818 ± 29 0.325
boost post-RT -789 ± 49 -810 ± 47 0.118
Figure 2 Skin late toxicity based on ctc v.2 criteria versus
toxicity grade for the 39 patients.
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toxicity based on FEV1% was observed in 62% and 5%
of smokers/non smokers, respectively (p < 0.001).
Discussion
Breast radiation therapy after conservative surgery is
now widely accepted as a standard of care for patients
with early breast cancer. Moreover breast conserving
therapy has become an accepted treatment option over
radical mastectomy for stage I - II breast tumour.
However, in some patients, such as the elderly and
those living faraway from radiation facilities, adjuvant
breast radiotherapy appears to be underutilized
because of the substantial length of the standard radia-
tion course. This usually consists of 50 Gy in 25 daily
fractions of 2 Gy to the whole breast usually followed
by the addition of a boost dose to the tumour bed of
10-16 Gy in 5 - 8 daily fractions, resulting in an overall
treatment time of 6 - 7 weeks. Delivering postoperative
radiotherapy in a shorter time could effectively be
much more convenient for these patients knocking
down the “logistical barriers” to the adjuvant breast
radiotherapy. Several clinical randomized trials have
shown that hypofractionated adjuvant radiotherapy in
breast cancer offers similar rates of tumour control
and normal tissue damage as the standard schedule
[7-9].
In our Institute patients refusing a 42-49 day lasting
treatment were offered an accelerated hypofractionated
schedule requiring 19 days. Despite this “aggressiveness”
the radiotherapy schedule investigated in this study (i.e
34 Gy in 3.4 Gy/fr plus boost dose of 8 Gy in single
fraction) was well tolerated and compliant. It is worth-
while to note that the early and late radiation toxicity
appeared remarkably low and comparable to standard
regime.
In particular, acute skin toxicity of Grade 0, 1, and 2
was experienced by 49%, 41.0% and 10% of patients
respectively; no patient experienced Grade 3 or more.
This toxicity was much lower than expected from stan-
dard radiotherapy [26].
G1 late skin toxicity was observed in 11 out of 39
patients with no G2 or more.
No correlation between chemotherapy and skin toxi-
city was found. However, due to the low number of
patients receiving chemotherapy (12/39) and the differ-
ent schedules of chemotherapy (CMF or FEC or EC fol-
lowed by Docetaxel) used, further patients are needed to
confirm this finding.
No patient referred symptoms of radiation pneumoni-
tis or other respiratory symptoms or problems clinically
related to radiotherapy. No CT-lung toxicity was
denoted by the radiologist on CT-scans acquired at 1
year post-radiotherapy. These results are comparable
with those reported in other studies where early and
late lung toxicity after standard or hypofractionated
radiotherapy to the breast only was studied [15,27,28].
Bentzen et al. reported enhanced RT-induced pulmon-
ary fibrosis in patients treated with concomitant tamoxi-
fen [29]. This effect was not observed in our cohort of
patients.
In accordance with Wennemberg et al. [25] no corre-
lation was found between HU and either chemotherapy
or TAM.
Table 5 DLCO and FEV1% measured before and at 2 year post-radiotherapy against chemotherapy, TAM and smoking
habits.
Adverse Event group Percentage of ≥G1 grade p (§) Percentage of ≥G2 grade p (§)
DLCO measured before radiotherapy respect to predicted value for each patient
Chemotherapy vs no chemotherapy 78% vs. 22% 0.006 38% vs 6% 0.036
TAM vs no TAM 43% vs. 44% 0.755 14% vs 17% 0.972
Smoking vs no smoking 67% vs. 31% 0.111 44% vs 19% 0.299
DLCO measured at 2 year post-radiotherapy respect to predicted value for each patient
Chemotherapy vs no chemotherapy 67% vs. 41% 0.251 45% vs 19% 0.258
TAM vs no TAM 44% vs. 52% 0.848 25% vs 29% 0.993
Smoking vs no smoking 54% vs. 46% 0.930 31% vs 17% 0.538
FEV1% measured before radiotherapy respect to predicted value for each patient
Chemotherapy vs no chemotherapy 40% vs. 42% 0.765 0% vs. 0% -
TAM vs no TAM 36% vs. 43% 0.996 0% vs. 0% -
Smoking vs no smoking 40% vs. 41% 0.882 0% vs. 0% -
FEV1% measured at 2y-post-radiotherapy respect to predicted value for each patient
Chemotherapy vs no chemotherapy 44% vs. 50% 0.890 0% vs. 4% 0.673
TAM vs no TAM 44% vs. 56% 0.464 0% vs 6% 0.853
Smoking vs no smoking 62% vs. 5% <0.001 0% vs 5% 0.931
(§) p-value chi-square test
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was certainly also related, in our series, to the very low
values of doses administered to the lung volume as
shown from the calculated dose volume histograms.
Statistically significant changes in toxicity ≥G2 and
≥G1 based on DLCO (p = 0.006 and p = 0.034, respec-
tively) were detected when comparing data of patients
who did receive chemo-therapy and those who did not,
but no adjunctive effects were seen due to radiotherapy.
These findings are in accordance with the low observed
mean DLCO caused by the adjuvant chemotherapy
[27,30]. This confirms that DLCO is a more sensitive
variable of functional pulmonary changes due to drug-
induced toxicity.
These differences were lost at 2 years post-radiother-
apy indicating recovery over time and no additional
influence of hypo-fractionated radiotherapy schedule.
These results confirm the literature [27], indicating a
trend towards normalization at 5 months after
radiotherapy.
FEV1% showed a significant correlation with smoking
habits for ≥G1 toxicity at 2-years post-radiotherapy.
Our findings support the hypothesis that this new
hypofractionated schedule neither implies a detriment of
functional breathing nor hinders the recovery over time.
Conclusion
The radiotherapy schedule investigated in this study (i.e
34 Gy in 3.4 Gy/fr plus boost dose of 8 Gy in single
fraction) is a feasible and safe treatment and does not
lead to adjunctive acute and late toxicities. A longer fol-
low up is expected to confirm these favourable results.
Still, randomized prospective studies, designed to vali-
date accelerated hypofractionated schedules, should be
encouraged.
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